"As the COVID-19 outbreak spreads, we are committed to getting you the information and care you need. The Mount Sinai Health System is also taking extra precautions to provide the safest environment possible during this time."

During the past decade, Mount Sinai Faculty Practice Associates conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mount Sinai Faculty Practice Associates" #1 sponsor was "Blue Earth Diagnostics" with 2 trials, followed by "Human Genome Sciences Inc." with 2 trials sponsored, "Aesculap Biologics, LLC" with 1 trials sponsored, "Bayer" with 1 trials sponsored and "Exact Sciences Corporation" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mount Sinai Faculty Practice Associates" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Parexel" with 2 trials as a collaborator, "Onset Therapeutics, Inc" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Mount Sinai Faculty Practice Associates" are "Chronic Hepatitis C" (2 trials), "Prostate Cancer" (2 trials), "Articular Cartilage of the Femoral Condyle Between 2-6cm2" (1 trials), "Atopic Dermatitis" (1 trials) and "Colonic Diseases" (1 trials). Many other conditions were trialed in "Mount Sinai Faculty Practice Associates" in a lesser frequency.

Most popular intervention types in "Mount Sinai Faculty Practice Associates" are "Drug" (6 trials), "Biological" (1 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ribavirin" (2 trials), "albumin interferon alfa-2b" (2 trials), "peginterferon alfa-2a" (2 trials), "rhPSMA-7.3 (18F) Injection" (2 trials) and "ADT" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mount Sinai Faculty Practice Associates" are 6 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Mount Sinai Faculty Practice Associates". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Mount Sinai Faculty Practice Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mount Sinai Faculty Practice Associates, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".